Biotechnology
Technology
Health

Kadmon

$2.82
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.06 (2.17%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Kadmon and other stocks, options, ETFs, and crypto commission-free!

About

Kadmon Holdings, Inc., also called Kadmon, is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. It focuses on the treatment of autoimmune, inflammatory, and fibrotic diseases. Read More Its products include Ribasphere, RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine. The company was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.

Employees
116
Headquarters
New York, New York
Founded
2010
Market Cap
312.24M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
782.65K
High Today
$2.85
Low Today
$2.74
Open Price
$2.75
Volume
104.71K
52 Week High
$4.46
52 Week Low
$1.88

Collections

Biotechnology
Technology
Health
Biopharmaceutical
Pharmaceutical
2016 IPO
US
North America

News

Yahoo FinanceMar 22

Kadmon Announces Susan Wiviott to Step Down from Board of Directors

NEW YORK, NY / ACCESSWIRE / March 22, 2019 / Kadmon Holdings, Inc. (KDMN) today announced that Susan Wiviott does not intend to stand for re-election to Kadmon's Board of Directors at the upcoming annual meeting of shareholders on May 15, 2019 (the "Annual Meeting"). On March 21, 2019, Ms. Wiviott provided notice to the Company of her intent to resign effective as of the Annual Meeting, and confirmed that her intent to not stand for re-election is not because of any disagreement between her and the Company....

27
Yahoo FinanceMar 13

When Will Kadmon Holdings, Inc. (NYSE:KDMN) Become Profitable?

Kadmon Holdings, Inc.’s (NYSE:KDMN): Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The US$379m market-cap company announced a latest loss of -US$56.3m on 31 December 2018 for its most recent financial year result. The most pressing concern for investors is KDMN’s path to profitability – when will it breakeven? I’ve put together a brief outline of industry analyst exp...

133
Yahoo FinanceMar 13

Kadmon to Present at the Oppenheimer 29th Annual Healthcare Conference

NEW YORK, NY / ACCESSWIRE / March 13, 2019 / Kadmon Holdings, Inc. (KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at Oppenheimer's 29th Annual Healthcare Conference in New York on Tuesday, March 19 at 2:10 p.m. ET. A live audio webcast of the presentation may be accessed on the Investors section of the Kadmon website at www.kadmon.com . A replay of the webcast will be available for 90 days. About Kadmon Holdings, Inc. Kadmon Holdings, Inc. is a ful...

13

Earnings

-$0.45
-$0.34
-$0.24
-$0.13
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.